Labcorp Holdings annual free cash flow
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Labcorp Holdings Free Cash Flow (FCF) History (LH)
Labcorp Holdings reported $1.21B in free cash flow for fiscal 2025, an increase of 10.05% from the previous fiscal year, with a free cash flow margin of 8.64%.
View full Labcorp Holdings company overviewLabcorp Holdings free cash flow by year
| Fiscal year | Period ended | Free cash flow | Change | Growth | FCF margin |
|---|---|---|---|---|---|
| 2025 | 2025-12-31 | $1.21B | $110.1M | +10.05% | +8.64% |
| 2024 | 2024-12-31 | $1.10B | $221.8M | +25.37% | +8.42% |
| 2023 | 2023-12-31 | $874.1M | −$652.5M | −42.74% | +7.19% |
| 2022 | 2022-12-31 | $1.53B | −$1.16B | −43.21% | +12.87% |
| 2021 | 2021-12-31 | $2.69B | $934.5M | +53.29% | +20.46% |
| 2020 | 2020-12-31 | $1.75B | $709.1M | +67.89% | +12.54% |
| 2019 | 2019-12-31 | $1.04B | $118.9M | +12.85% | +9.04% |
| 2018 | 2018-12-31 | $925.6M | −$259.6M | −21.90% | +8.17% |
| 2017 | 2017-12-31 | $1.19B | $267.0M | +29.08% | +11.50% |
| 2016 | 2016-12-31 | $918.2M | $191.6M | +26.37% | +9.61% |
| 2015 | 2015-12-31 | $726.6M | $191.1M | +35.69% | +8.37% |
| 2014 | 2014-12-31 | $535.5M | −$81.0M | −13.14% | +8.91% |
| 2013 | 2013-12-31 | $616.5M | −$51.1M | −7.65% | +10.61% |
| 2012 | 2012-12-31 | $667.6M | −$42.3M | −5.96% | +11.77% |
| 2011 | 2011-12-31 | $709.9M | −$47.6M | −6.28% | +12.81% |
| 2010 | 2010-12-31 | $757.5M | $9.8M | +1.31% | +15.14% |
| 2009 | 2009-12-31 | $747.7M | $123.5M | +19.79% | +15.93% |
| 2008 | 2008-12-31 | $624.2M | $57.1M | +10.07% | +13.86% |
| 2007 | 2007-12-31 | $567.1M | — | — | +13.94% |
Labcorp Holdings quarterly free cash flow
Q3.08
Q1.09
Q2.09
Q3.09
Q4.09
Q1.10
Q2.10
Q3.10
Q4.10
Q1.11
Q2.11
Q3.11
Q4.11
Q1.12
Q2.12
Q3.12
Q4.12
Q1.13
Q2.13
Q3.13
Q4.13
Q1.14
Q2.14
Q3.14
Q4.14
Q1.15
Q2.15
Q3.15
Q4.15
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Free cash flow | Change | YoY growth | FCF margin |
|---|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $313.9M | −$228.8M | −42.16% | +8.41% |
| Q1 2026 | 2026-03-31 | $70.5M | $178.0M | — | +1.99% |
| Q4 2025 | 2025-12-31 | $490.3M | −$174.8M | −26.28% | +13.95% |
| Q3 2025 | 2025-09-30 | $280.5M | $119.0M | +73.68% | +7.87% |
| Q2 2025 | 2025-06-30 | $542.7M | $109.8M | +25.36% | +15.39% |
| Q1 2025 | 2025-03-31 | −$107.5M | $56.1M | — | −3.21% |
| Q4 2024 | 2024-12-31 | $665.1M | $252.7M | +61.28% | +19.98% |
| Q3 2024 | 2024-09-30 | $161.5M | −$9.1M | −5.33% | +4.92% |
| Q2 2024 | 2024-06-30 | $432.9M | $184.8M | +74.49% | +13.44% |
| Q1 2024 | 2024-03-31 | −$163.6M | −$206.6M | — | −5.15% |
| Q4 2023 | 2023-12-31 | $412.4M | −$142.1M | −25.63% | +13.60% |
| Q3 2023 | 2023-09-30 | $170.6M | −$120.4M | −41.37% | +5.58% |
| Q2 2023 | 2023-06-30 | $248.1M | −$194.2M | −43.91% | +8.18% |
| Q1 2023 | 2023-03-31 | $43.0M | −$195.8M | −81.99% | +1.42% |
| Q4 2022 | 2022-12-31 | $554.5M | −$31.9M | −5.44% | +25.50% |
| Q3 2022 | 2022-09-30 | $291.0M | −$358.5M | −55.20% | +10.15% |
| Q2 2022 | 2022-06-30 | $442.3M | $52.3M | +13.41% | +15.13% |
| Q1 2022 | 2022-03-31 | $238.8M | −$823.4M | −77.52% | +6.12% |
| Q4 2021 | 2021-12-31 | $586.4M | −$88.8M | −13.15% | +54.74% |
| Q3 2021 | 2021-09-30 | $649.5M | −$59.5M | −8.39% | +15.99% |
| Q2 2021 | 2021-06-30 | $390.0M | $117.8M | +43.28% | +10.15% |
| Q1 2021 | 2021-03-31 | $1.06B | $965.0M | +992.80% | +25.52% |
| Q4 2020 | 2020-12-31 | $675.2M | $233.6M | +52.90% | +15.04% |
| Q3 2020 | 2020-09-30 | $709.0M | $346.0M | +95.32% | +18.20% |
| Q2 2020 | 2020-06-30 | $272.2M | $103.9M | +61.73% | +9.83% |
| Q1 2020 | 2020-03-31 | $97.2M | $25.6M | +35.75% | +3.44% |
| Q4 2019 | 2019-12-31 | $441.6M | $77.4M | +21.25% | +14.95% |
| Q3 2019 | 2019-09-30 | $363.0M | $209.0M | +135.71% | +12.40% |
| Q2 2019 | 2019-06-30 | $168.3M | −$131.9M | −43.94% | +5.84% |
| Q1 2019 | 2019-03-31 | $71.6M | −$35.6M | −33.21% | +2.57% |
| Q4 2018 | 2018-12-31 | $364.2M | −$104.7M | −22.33% | +13.07% |
| Q3 2018 | 2018-09-30 | $154.0M | −$167.4M | −52.08% | +5.44% |
| Q2 2018 | 2018-06-30 | $300.2M | $59.0M | +24.46% | +10.47% |
| Q1 2018 | 2018-03-31 | $107.2M | −$46.5M | −30.25% | +3.76% |
| Q4 2017 | 2017-12-31 | $468.9M | $73.1M | +18.47% | +17.08% |
| Q3 2017 | 2017-09-30 | $321.4M | $137.7M | +74.96% | +12.26% |
| Q2 2017 | 2017-06-30 | $241.2M | −$41.3M | −14.62% | +9.54% |
| Q1 2017 | 2017-03-31 | $153.7M | $97.5M | +173.49% | +6.37% |
| Q4 2016 | 2016-12-31 | $395.8M | $96.3M | +32.15% | +16.58% |
| Q3 2016 | 2016-09-30 | $183.7M | −$36.5M | −16.58% | +7.61% |
| Q2 2016 | 2016-06-30 | $282.5M | −$45.1M | −13.77% | +11.62% |
| Q1 2016 | 2016-03-31 | $56.2M | $176.9M | — | +0.58% |
| Q4 2015 | 2015-12-31 | $299.5M | $132.1M | +78.91% | +13.34% |
| Q3 2015 | 2015-09-30 | $220.2M | $97.2M | +79.02% | +9.50% |
| Q2 2015 | 2015-06-30 | $327.6M | $815.8M | — | +14.44% |
| Q1 2015 | 2015-03-31 | −$120.7M | −$656.2M | — | −6.73% |
| Q4 2014 | 2014-12-31 | $167.4M | −$21.7M | −11.48% | +11.07% |
| Q3 2014 | 2014-09-30 | $123.0M | −$59.1M | −32.45% | +7.93% |
| Q2 2014 | 2014-06-30 | −$488.2M | −$577.0M | — | −32.19% |
| Q1 2014 | 2014-03-31 | $535.5M | $379.0M | +242.17% | +8.91% |
| Q4 2013 | 2013-12-31 | $189.1M | −$3.7M | −1.92% | +13.16% |
| Q3 2013 | 2013-09-30 | $182.1M | $22.4M | +14.03% | +12.45% |
| Q2 2013 | 2013-06-30 | $88.8M | −$63.4M | −41.66% | +6.05% |
| Q1 2013 | 2013-03-31 | $156.5M | −$6.4M | −3.93% | +10.86% |
| Q4 2012 | 2012-12-31 | $192.8M | −$55.7M | −22.41% | +13.72% |
| Q3 2012 | 2012-09-30 | $159.7M | $23.3M | +17.08% | +11.25% |
| Q2 2012 | 2012-06-30 | $152.2M | $13.1M | +9.42% | +10.69% |
| Q1 2012 | 2012-03-31 | $162.9M | −$23.0M | −12.37% | +11.45% |
| Q4 2011 | 2011-12-31 | $248.5M | $22.1M | +9.76% | +18.19% |
| Q3 2011 | 2011-09-30 | $136.4M | −$5.5M | −3.88% | +9.71% |
| Q2 2011 | 2011-06-30 | $139.1M | −$42.6M | −23.45% | +9.91% |
| Q1 2011 | 2011-03-31 | $185.9M | −$21.6M | −10.41% | +13.59% |
| Q4 2010 | 2010-12-31 | $226.4M | $39.3M | +21.00% | +17.48% |
| Q3 2010 | 2010-09-30 | $141.9M | −$81.8M | −36.57% | +11.12% |
| Q2 2010 | 2010-06-30 | $181.7M | $23.0M | +14.49% | +14.67% |
| Q1 2010 | 2010-03-31 | $207.5M | $29.3M | +16.44% | +17.38% |
| Q4 2009 | 2009-12-31 | $187.1M | — | — | +16.06% |
| Q3 2009 | 2009-09-30 | $223.7M | $70.8M | +46.30% | +18.88% |
| Q2 2009 | 2009-06-30 | $158.7M | — | — | +13.35% |
| Q1 2009 | 2009-03-31 | $178.2M | — | — | +15.42% |
| Q3 2008 | 2008-09-30 | $152.9M | — | — | +13.47% |
Labcorp Holdings free cash flow growth trends
Over the last five reported fiscal years, free cash flow declined from $1.75B to $1.21B, a compound annual decline of 7.21%. Labcorp Holdings's latest reported quarter, Q2 2026, generated $313.9M in free cash flow, a decrease of 42.16% year over year.
About the metric
What free cash flow means
Free cash flow is the cash a company generates from operations after capital expenditures. Positive FCF can fund dividends, buybacks, debt repayment, or reinvestment; negative FCF means capital spending exceeded operating cash flow for that period.
Calculation and source
How free cash flow is calculated
TickerStat calculates free cash flow as reported operating cash flow minus capital expenditures. FCF margin equals free cash flow divided by revenue. Fiscal periods can differ from calendar years, so the tables include exact period-end dates.
Review Labcorp Holdings source filings ↗Community posts
Labcorp sets new medium-term growth targets and reaffirms its annual outlook
Labcorp ($LH) set medium-term targets for annual revenue growth of 5–8% and adjusted earnings-per-share growth of 8.5–11.5% through 2029. The company also reaffirmed its existing 2026 guidance. The new framework describes the performance ma ...
Labcorp acquires MLM Medical Labs to expand clinical-trial services
Labcorp ($LH) acquired MLM Medical Labs, adding central and specialty laboratory operations in the United States, Germany and South Africa. The company said the purchase expands its biomarker-testing capabilities and improves its ability to ...
